Lysostaphin, an enzyme that rapidly lyses the cell walls of Staphylococcus aureus (11, 13, 14) , is effective in the treatment of established staphylococcal infections in experimental animals (5, 6, 12) . Its action is thought to be due to a peptidase that cleaves cell wall polyglycine bridges and is found almost exclusively in coagulase-positive staphylococci (3) . Lysostaphin is, therefore, a uniquely specific agent. It is effective in vitro against S. aureus strains irrespective of their phage susceptibility or their resistance to conventional antibiotics including methicillin (4, 15) but has no effect on bacteria of other genera.
Persistent nasal carriers, especially in a hospital setting, are an important source of S. aureus. Conventional antibacterial therapy, whether topical or systemic, has not consistently eliminated S. aureus from the nasal passages of such carriers, but topical lysostaphin has produced promising results with small groups of normal adults (8, 9) and children (7) . This paper describes a controlled study of the effect of lysostaphin nasal spray on a rigorously defined group of persistent S. aureus nasal carriers in an institution for the mentally retarded. Figure 1 depicts the percentage of persistent carriers harboring S. aureus in their anterior nares before and after therapy. On the first day after completion of therapy, only 40% of the lysostaphin-treated group and 63% of those receiving Neosporin carried S. aureus. Both of these values are significantly lower than the 97% carrier rate among controls (P < 0.01). The difference between the lysostaphin and Neosporin groups is not significant. However, 5 days after therapy only 60% of the lysostaphin-treated individuals carried S. aureus, whereas 94% of the Neosporin group and 97% of controls were again carriers. At this point, the carriage rate among the lysostaphin-treated individuals was significantly below that for both the Neosporin and control groups (P < 0.05). By the 11th and 24th days after therapy, no significant differences existed among the groups.
MATERIALS AND METHODS
Only 36%o of the lysostaphin group was positive on all post-treatment cultures, as opposed to 64% of the Neosporin group and 91% of the controls. The lysostaphin group differs significantly from the controls (P < 0.0005) but not from the Neosporin group which, in turn, is not significantly different from the control group.
In Table 1 , the persistence, elimination, and acquisition of phage types in the three treatment groups are compared. Of the phage types present before therapy, 29% were eliminated after lysostaphin therapy, 24% were eliminated after Neosporin, and 6% were eliminated in the control group. The elimination of phage types during lysostaphin therapy was significantly greater than that which occurred in the control group (P < 0.01). However, the elimination of phage types after Neosporin did not differ significantly from that of the lysostaphin or control groups. Acquisition of new phage types occurred with similar frequency in all three groups. No lysostaphin-resistant strains were detected either before or after therapy. The greatest minimum inhibitory concentration recorded was 1.6 ;Lg/ml. Likewise, no strains resistant to either neomycin or bacitracin were detected.
Immunology. No local or systemic reactions were detected in those treated either once or twice with intranasal lysostaphin.
Skin test results with lysostaphin are presented in Table 2 . Both erythema and induration were somewhat more frequent in patients previously exposed to lysostaphin than in the controls, but none of these differences is statistically significant. A wheal and flair reaction at 30 min occurred in one person who had been exposed previously to lysostaphin. This reaction subsided within 2 hr, and the patient experienced no delayed or systemic reactions.
Lysostaphin hemagglutination-inhibition titers in 54 individuals with no known exposure to lysostaphin were distributed in a biphasic manner (Fig. 2) . Thirty-six (67%) had titers of less than 2 Because of the unpredictable and frequently inadequate response to conventional intranasal or systemic antibiotics, new therapeutic approaches, such as lysostaphin, are being investigated (7) (8) (9) .
Intranasal lysostaphin spray significantly reduced the number of carriers of S. aureus in the mentally retarded, rigorously defined persistent carriers used as subjects in this study. This effect was apparent on the 2nd and 5th days after the completion of therapy but was not detectable 11 days after treatment was stopped. Carriage rates among the Neosporin group had returned to pretreatment levels by the 5th day after therapy; thus, the effect of lysostaphin is slightly more prolonged than that of Neosporin.
Martin and White (9) noted a 91% reduction in carriage of S. aureus after intranasal lysostaphin treatment of healthy medical personnel, with a partial effect persisting for 4 months after therapy. Harris et al. (7) rendered 10 pediatric carriers culture-negative for periods of 10 to 53 days with intranasal lysostaphin. The greater efficacy of lysostaphin in those two studies compared with the present investigation can be attributed to several factors. (i) The persistent carrier state was more rigorously defined in the current study.
(ii) All individuals in the present study, institutionalized because of mental retardation, were in close contact possibly facilitating interpersonal transfer of strains. (iii) The duration of therapy was shorter than in the previous studies. Thus, the current investigation constituted a more rigorous test of therapeutic efficacy than did the previous studies.
Eradication of all S. aureus from the anterior nares is not necessarily the only criterion of successful treatment. In an epidemiologically important carrier, eradication of the specific phage type of S. aureus causing infections may be sufficient, even if the individual continues to carry other strains of S. aureus. In the present study, lysostaphin therapy was followed by a signifi- 
